US tariffs on generic drugs

What happened: President Trump announced phased tariffs on imported generic drugs, starting with zero tariffs for two years, then 100% in August 2028, and 200% a year later. This is aimed at encouraging manufacturers to shift production to the U.S. Trump's initial proposal of up to 200% tariffs raised concerns about higher medicine prices and supply chain shifts.

Market impact: Indian pharmaceutical companies, such as Sun Pharmaceutical Industries and Dr. Reddy's Laboratories, are significantly exposed to U.S. markets and face potential disruption. U.S. generic drugmakers like Mylan and Teva could benefit from reduced competition. UBS and Goldman Sachs warn of increased production costs and potential reshoring of manufacturing.

What to watch next: The two-year grace period ends in August 2026, after which manufacturers must decide on production shifts. In the meantime, monitor earnings reports from affected companies to gauge their strategies and cost structures. Additionally, track regulatory developments, as the Trump administration's plans may face challenges or changes.